US 12,279,810 B2
RF ablation catheter for treating hypertrophic cardiomyopathy and method of treating hypertrophic cardiomyopahty by using same
June Hong Kim, Busan (KR); Gi-Byoung Nam, Seoul (KR); and Kyone Peter Park, Yangsan (KR)
Assigned to TAU MEDICAL INC., (KR); THE ASAN FOUNDATION, (KR); and UNIVERSITY OF ULSAN FOUNDATAION FOR INDUSTRY COOPERATION, (KR)
Filed by TAU MEDICAL INC., Busan (KR)
Filed on Dec. 31, 2022, as Appl. No. 18/092,277.
Application 18/092,277 is a division of application No. 16/690,115, filed on Nov. 20, 2019, abandoned.
Claims priority of application No. 10-2018-0144864 (KR), filed on Nov. 21, 2018; and application No. 10-2019-0012874 (KR), filed on Jan. 31, 2019.
Prior Publication US 2023/0172660 A1, Jun. 8, 2023
Int. Cl. A61B 18/14 (2006.01); A61B 18/00 (2006.01)
CPC A61B 18/1492 (2013.01) [A61B 2018/00023 (2013.01); A61B 2018/00357 (2013.01); A61B 2018/00904 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method of treating hypertrophic cardiomyopathy in a human heart, comprising:
positioning a guidewire in an interventricular septum through a septal vein in the heart;
positioning on the guidewire an RF ablation catheter at least one selected target position proximate a His bundle, the RF ablation catheter comprising at least an intraseptal insertion part having a tapered tip, a first guidewire insertion hole defined in the tip and having a radius dimensioned to receive the guidewire therethrough, and a plurality of RF ablation electrodes embedded in a peripheral surface thereof, and a body part connected to the insertion part; and
selectively energizing at least one of the plurality of RF ablation electrodes.